Overview

Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals